The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.

ABSTRACT:

Background

Resistance to chemotherapy, combined with heterogeneity among resistant tumors, represents a significant challenge in the clinical management of triple negative breast cancer (TNBC). By dissecting molecular pathways associated with treatment resistance, we sought to define patient sub-groups and actionable targets for next-line treatment.

Methods

Bulk RNA sequencing and reverse phase protein array profiling were performed on isogenic patient-derived xenografts (PDX) representing paclitaxel-sensitive and -resistant tumors. Pathways identified as upregulated in the resistant model were further explored as targets in PDX explants. Their clinical relevance was assessed in two distinct patient cohorts (NeoAva and MET500).

Results

Increased activity in signaling

SUBMITTER: Egeland EV 

PROVIDER: S-EPMC11554838 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature